Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05008419 · ClinicalTrials.gov registry record · NA
Narrative Discourse Treatment Development
A NA study of Traumatic Brain Injury and Neurogenic Communication Disorders, sponsored by VA Office of Research and Development.
- Active
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05008419: Active NA study of Traumatic Brain Injury and Neurogenic Communication Disorders, sponsored by VA Office of Research and Development.
NCT05008419 is a NA study of Traumatic Brain Injury and Neurogenic Communication Disorders that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 34 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05008419, a NA study of Traumatic Brain Injury and Neurogenic Communication Disorders, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Discourse impairments are breakdowns in meaningful communication beyond the level of single sentences and have a functional impact on the lives of Veterans with TBI, disrupting return to work, communication re integration, socialization, and quality of life. The few prior attempts to treat discourse impairments have been small case studies and resulted in no change or limited gains. The proposed study evaluates the feasibility of a novel narrative discourse treatment that builds upon these prior attempts by addressing breakdowns in both story content and story organization using a theoretically-driven approach. If feasible, as demonstrated by tolerability and acceptability to participants, and later shown to be effective, the proposed discourse treatment has the potential to improve daily communication, which provides a gateway for Veterans with TBI to increase meaningful participation and improve functioning in major life domains.
Primary Outcome
Rates of attendance for all aspects of treatment, calculated as the number of treatment sessions attended across all treatment phases divided by total number of treatment sessions.
Conditions Studied
Interventions
- BEHAVIORAL Narrative discourse treatment
Study Locations (1)
Connecticut
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What the registry record for NCT05008419 still lists
NCT05008419 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Traumatic Brain Injury appearing as the primary indexed condition, and to 1 intervention - of which Narrative discourse treatment is the first listed.
NCT05008419 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05008419 about?
NCT05008419 is a clinical study titled "Narrative Discourse Treatment Development". Discourse impairments are breakdowns in meaningful communication beyond the level of single sentences and have a functional impact on the lives of Veterans with TBI, disrupting return to work, communication re integration, socialization, and quality of life. The few prior attempts to treat discourse...
What is the current status of trial NCT05008419?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 34 participants. The study started on 2023-11-27. Estimated completion is 2026-09-30.
What conditions does trial NCT05008419 study?
This clinical trial studies the following conditions: Traumatic Brain Injury, Neurogenic Communication Disorders.
What interventions are being tested in trial NCT05008419?
The interventions under investigation include: Narrative discourse treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT05008419?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05008419 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05008419's enrollment target sits among peer trials
34 134th of 171 higher than 36 of 171 other Traumatic Brain Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Traumatic Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
tPBM in Older Adults With Traumatic Brain Injury
RECRUITING · NA
-
Carbon Dioxide Administration and Brain Waste Clearance
RECRUITING · NA
-
TMS-fNIRS Personalized Dosing
RECRUITING · NA
-
Community-based Implementation of Online EmReg
RECRUITING · NA
-
Evaluation of the Abbott i-STAT TBI Biomarker Test
RECRUITING · NA
-
Long-term Brain Stimulation of the Motor Ventral Thalamus (VOP/VIM) to Improve Motor Function
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI